Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3387-3395

  Bourbeau, Denis ^a   Lau, Cara Jean ^b,c   Jaime, Jairo ^a   Koty, Zafiro ^c   Zehntner, Simone P ^c   Lavoie, Geneviève ^a   Mes Masson, Anne Marie ^d   Nalbantoglu, Josephine ^b,c   Massie, Bernard ^a,e,f  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Institut du Cancer de Montreal   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE; FLUCYTOSINE; PROTEINASE; URACIL PHOSPHORIBOSYLTRANSFERASE; VIRUS PROTEIN; FLUOROURACIL; GLYCOSYLTRANSFERASE; PEPTIDE HYDROLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TRANSFORMATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE NUMBER; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE THERAPY; TUMOR CELL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; C57BL MOUSE; ENZYMOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; GLIOBLASTOMA; METABOLISM; METHODOLOGY; MULTICELLULAR SPHEROID; NUDE MOUSE; PHYSIOLOGY; TRANSGENE; TUMOR CELL LINE; VIRUS GENOME;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENE AMPLIFICATION; GENE THERAPY; GENETIC VECTORS; GENOME, VIRAL; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; PENTOSYLTRANSFERASES; PEPTIDE HYDROLASES; SPHEROIDS, CELLULAR; TRANSGENES; VIRUS REPLICATION;

EID: 34248223025     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4317     Document Type: Article

References (48)

1. Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999;35:867-85.
2. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001;187:22-36.
3. Bourbeau D, Lavoie G, Nalbantoglu J, Massie B. Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status. J Gene Med 2004;6:1320-32.
4. Grill J, Lamfers ML, van Beusechem VW, et al. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 2002;6: 609-14.
5. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21:2508-18.
6. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 2003;3:13-26.
7. Griscelli F, Opolon P, Saulnier P, et al. Recombinant adenovirus sheading after intratumoral gene transfer in lung cancer patients. Gene Ther 2003;10:386-95.
8. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999;10:1239-49.
9. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003;14:227-41.
10. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8:89-98.
11. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003;14:933-46.
12. Oualikene W, Lamoureux L, Weber JM, Massie B. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy. Hum Gene Ther 2000;11:1341-53.
13. Weber JM. Adenain, the adenovirus endoprotease [a review]. Acta Microbiol Immunol Hung 2003;50:95-101.
14. Tiraby M, Cazaux C, Baron M, et al. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998;167:41-9.
15. Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998;58: 1946-51.
16. Provencher DM, Lounis H, Champoux L, et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000;36:357-61.
17. Mullick A, Xu Y, Warren R, et al. The cumate gene-switch: a system for regulated expression in mammalian cells. BMC Biotechnol 2006:6:43.
18. Qiao J, Roy V, Girard MH, Caruso M. High translation efficiency is mediated by the encephalomyocarditis virus internal ribosomal entry sites if the natural sequence surrounding the eleventh AUG is retained. Hum Gene Ther 2002;13:881-7.
19. Li H, Alonso-Vanegas M, Colicos MA, et al. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 1999;5:637-42.
20. Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther 2003;10:388-95.
21. Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002;62: 3812-8.
22. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998;9:2363-73.
23. Kim M, Zinn KR, Barnett BG, et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002;38:1917-26.
24. You Z, Fischer DC, Tong X, et al. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther 2001;8:168-75.
25. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins avp3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-19.
26. Davison E, Kirby I, Whitehouse J, et al. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by α(v)β1 integrin and can be modulated by changes in β1 integrin function. J Gene Med 2001;3:550-9.
27. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001;61:813-7.
28. Pipiya T, Saurhoff H, Huang YQ, et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther 2005;12:911-7.
29. Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 2005;12:902-10.
30. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002;9:1022-35.
31. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002;62:6165-71.
32. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998;9:1323-33.
33. Wildner O, Morris JC, Vahanian NN, et al. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999;6:57-62.
34. Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;61:8743-50.
35. Stubdal H, Perin N, Lemmon M, et al. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res 2003;63: 6900-8.
36. Rogulski KR, Wing MS, Paielli DL, et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radio sensitization. Hum Gene Ther 2000;11:67-76.
37. Freytag SO, Paielli D, Wing M, et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002;54:873-85.
38. Lambright ES, Amin K, Wiewrodt R, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther 2001;8:946-53.
39. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46:171-9.
40. Khatri A, Zhang B, Doherty E, et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 2006;8:1086-96.
41. Pierrefite-Carle V, Baque P, Gavelli A, et al. Cytosine deaminase/5-fiuorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J Natl Cancer Inst 1999;91:2014-9.
42. Haack K, Linnebacher M, Eisold S, et al. Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther 2000;7:1357-64.
43. Camphausen K, Purow B, Sproull M, et al. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci U S A 2005;102:8287-92.
44. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-205.
45. Trask TW, Trask RP, Aguilar-Cordova E et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203.
46. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19: 2-12.
47. Conrad C, Miller CR, Ji Y, et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 2005;12:284-94.
48. Zagzag D, Miller DC, Chiriboga L, Yee H, Newcomb EW. Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain Pathol 2003;13:34-7.